Carbamate of general formula (I), wherein R1, R2, and R3 are H, OH, NO.sub.2, SH, CN, F, Cl, Br, I, COOH, CONH.sub.2, (C.sub.1-C.sub.4)-alkoxycarbonyl, (C.sub.1-C.sub.4)-alkylsulfanyl, (C.sub.1-C.sub.4)-alkylsulfinyl, (C.sub.1-C.sub.4)-alkylsulfonyl, (C.sub.1-C.sub.4)-alkoxyl optionally substituted with one or several F, and (C.sub.1-C.sub.4)-alkyl optionally substituted with one or several F or OH; R4 is cycloalkyl, phenyl, heteroaryl or a bicyclic ring system; R5 is cycloalkyl, (C.sub.5-C.sub.10)-alkyl, a substituted (C.sub.1-C.sub.10)-alkyl; and X.sup.- is a physiologically acceptable anion. Carbamate (I) is selective M.sub.3 receptor antagonists versus M.sub.2 receptor and may be used for the treatment of urinary incontinence (particularly, the one caused by overactive bladder), irritable bowel syndrome, and respiratory disorders (particularly, chronic obstructive pulmonary disease, chronic bronchitis, asthma, emphysema, and rhinitis), as well as in ophthalmic interventions. ##STR00001##

 
Web www.patentalert.com

< Process for obtaining tolterodine

> Therapeutic combinations for the treatment or prevention of depression

~ 00476